A phase 3 trial shows no impact of the anticoagulant rivaroxaban on the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk — highlighting the need for a better understanding of the mechanisms that link these conditions.
Understanding the link between atrial fibrillation and cognitive decline / M. Proietti, G.F. Romiti. - In: NATURE MEDICINE. - ISSN 1078-8956. - 32:1(2026 Jan), pp. 40-41. [10.1038/s41591-025-04127-2]
Understanding the link between atrial fibrillation and cognitive decline
M. Proietti
;
2026
Abstract
A phase 3 trial shows no impact of the anticoagulant rivaroxaban on the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk — highlighting the need for a better understanding of the mechanisms that link these conditions.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
s41591-025-04127-2.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Licenza:
Nessuna licenza
Dimensione
898.77 kB
Formato
Adobe PDF
|
898.77 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
